Skip to main content

A novel technology enabling efficient delivery of personalized probiotics to prevent gut-related diseases and recover damaged gut microbiota

Project description

A novel technology for personalised probiotics development

Disturbances in the gut microbiome are associated with many different diseases including diabetes, obesity and cancer. Despite the importance of the microbiome in health, available probiotics fail to deliver sufficient bacterial numbers and variety to colonise the gut. To address this problem, the EU-funded MBSelect project will exploit a recently developed technology capable of growing complex bacteria communities on micro-particles and placing them into capsules after drying. This technology enables, for the first time, the development of tailored microbiome-based probiotics fitted to any purpose, age or gender. The project will scale up this innovative technology to industrial level and undertake the necessary activities for its commercialisation.

Field of science

  • /natural sciences/biological sciences/microbiology/bacteriology

Call for proposal

H2020-EIC-SMEInst-2018-2020-3
See other projects for this call

Funding Scheme

SME-2b - SME Instrument (grant only and blended finance)
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

MYBIOTICS PHARMA LTD
Address
5 Golda Meir Blvd, Rth Floor
7414001 Ness Ziona
Israel
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 1 995 700